PGV

PGV operates at the intersection of neurotechnology, medical devices, digital health, and research tools, with EEG measurement as its central focus. Its described product range includes HARU-2, a patch-style EEG device with medical-device certification, and NAIS Manager, a web application for managing EEG measurement data and analysis outputs. This combination distinguishes the stated offering from a hardware-only proposition: PGV also provides EEG and sleep analysis services, connecting measurement equipment with data-management and analytical workflows. Japanese insurance eligibility for HARU-2 in 2023 is a notable marker of its clinical-market relevance, alongside its stated service to research institutions, healthcare providers, and businesses. Its competitive position is best understood from the product scope and certification milestone, rather than claims of category leadership. The company’s university-research origins also frame its focus on translating EEG measurement research into practical products and services.

The available funding history lists three rounds: a Seed round of ¥90 million, a Series A of ¥260.4 million, and a Series B of ¥150 million. The progression to a Series B and the participation of investors including Shionogi & Co., Ltd., Osaka University Venture Capital Co., Ltd., and Nippon Mektron Co., Ltd. indicate successive financing and investor involvement, but do not establish current financial performance or company scale. Product development provides a clearer operating milestone: HARU-2 became eligible for insurance coverage in Japan in 2023, extending its potential use into reimbursed clinical settings. PGV’s combination of EEG hardware, analysis services, and NAIS Manager suggests a broader product workflow than device sales alone. A career recruitment notice is also noted, although roles and dates are unspecified. Without dated rounds, employee figures, launch timelines, or revenue data, the company’s growth rate and post-2023 momentum remain difficult to determine.